Compare Biocon with Torrent Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

BIOCON vs TORRENT PHARMA - Comparison Results

BIOCON      Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

TORRENT PHARMA 
   Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    BIOCON TORRENT PHARMA BIOCON /
TORRENT PHARMA
 
P/E (TTM) x 35.0 39.0 89.6% View Chart
P/BV x 4.4 9.9 44.8% View Chart
Dividend Yield % 0.2 0.6 36.0%  

Financials

 BIOCON    TORRENT PHARMA
EQUITY SHARE DATA
    BIOCON
Mar-19
TORRENT PHARMA
Mar-19
BIOCON /
TORRENT PHARMA
5-Yr Chart
Click to enlarge
High Rs7071,964 36.0%   
Low Rs5541,245 44.5%   
Sales per share (Unadj.) Rs91.9453.4 20.3%  
Earnings per share (Unadj.) Rs16.725.8 64.8%  
Cash flow per share (Unadj.) Rs24.262.3 38.8%  
Dividends per share (Unadj.) Rs1.0017.00 5.9%  
Dividend yield (eoy) %0.21.1 15.0%  
Book value per share (Unadj.) Rs101.6279.2 36.4%  
Shares outstanding (eoy) m600.00169.22 354.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x6.93.5 193.9%   
Avg P/E ratio x37.762.2 60.6%  
P/CF ratio (eoy) x26.125.8 101.3%  
Price / Book Value ratio x6.25.7 108.0%  
Dividend payout %6.065.9 9.1%   
Avg Mkt Cap Rs m378,330271,513 139.3%   
No. of employees `0006.113.6 45.1%   
Total wages/salary Rs m11,65314,038 83.0%   
Avg. sales/employee Rs Th8,994.35,642.6 159.4%   
Avg. wages/employee Rs Th1,900.71,032.4 184.1%   
Avg. net profit/employee Rs Th1,635.3320.9 509.7%   
INCOME DATA
Net Sales Rs m55,14476,728 71.9%  
Other income Rs m1,444571 253.1%   
Total revenues Rs m56,58877,299 73.2%   
Gross profit Rs m15,88319,831 80.1%  
Depreciation Rs m4,4786,177 72.5%   
Interest Rs m7095,038 14.1%   
Profit before tax Rs m12,1409,187 132.1%   
Minority Interest Rs m90-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-3,570 0.0%   
Tax Rs m2,1231,254 169.4%   
Profit after tax Rs m10,0264,363 229.8%  
Gross profit margin %28.825.8 111.4%  
Effective tax rate %17.513.6 128.2%   
Net profit margin %18.25.7 319.7%  
BALANCE SHEET DATA
Current assets Rs m48,22850,375 95.7%   
Current liabilities Rs m30,37651,653 58.8%   
Net working cap to sales %32.4-1.7 -1,943.9%  
Current ratio x1.61.0 162.8%  
Inventory Days Days6892 74.2%  
Debtors Days Days8668 125.2%  
Net fixed assets Rs m64,13083,648 76.7%   
Share capital Rs m3,000846 354.5%   
"Free" reserves Rs m57,98046,397 125.0%   
Net worth Rs m60,98047,244 129.1%   
Long term debt Rs m15,76639,129 40.3%   
Total assets Rs m121,924141,209 86.3%  
Interest coverage x18.12.8 641.8%   
Debt to equity ratio x0.30.8 31.2%  
Sales to assets ratio x0.50.5 83.2%   
Return on assets %8.86.7 132.3%  
Return on equity %16.49.2 178.0%  
Return on capital %16.812.3 135.8%  
Exports to sales %28.10-   
Imports to sales %18.90-   
Exports (fob) Rs m15,506NA-   
Imports (cif) Rs m10,399NA-   
Fx inflow Rs m15,50622,103 70.2%   
Fx outflow Rs m10,3995,522 188.3%   
Net fx Rs m5,10716,581 30.8%   
CASH FLOW
From Operations Rs m11,54617,981 64.2%  
From Investments Rs m-7,138-2,413 295.8%  
From Financial Activity Rs m-2,417-13,145 18.4%  
Net Cashflow Rs m2,1032,380 88.4%  

Share Holding

Indian Promoters % 40.4 71.5 56.5%  
Foreign collaborators % 20.6 0.0 -  
Indian inst/Mut Fund % 8.4 7.0 119.7%  
FIIs % 10.7 12.6 84.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 19.9 8.8 226.1%  
Shareholders   109,995 26,511 414.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare BIOCON With:   NATCO PHARMA  FRESENIUS KABI ONCO.  FDC  ABBOTT INDIA  PANACEA BIOTECH  

Compare BIOCON With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens above 50,000-Mark; Tata Motors & Bajaj Finance Top Gainers(09:30 am)

Asian share markets rose for the third straight session today, tracking gains in US peers. The Nikkei is trading up by 0.7% and the Hang Seng is trading up by 0.1%.

Related Views on News

BIOCON Announces Quarterly Results (2QFY21); Net Profit Down 23.9% (Quarterly Result Update)

Oct 29, 2020 | Updated on Oct 29, 2020

For the quarter ended September 2020, BIOCON has posted a net profit of Rs 2 bn (down 23.9% YoY). Sales on the other hand came in at Rs 17 bn (up 11.0% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

TORRENT PHARMA Announces Quarterly Results (2QFY21); Net Profit Up 27.0% (Quarterly Result Update)

Oct 27, 2020 | Updated on Oct 27, 2020

For the quarter ended September 2020, TORRENT PHARMA has posted a net profit of Rs 3 bn (up 27.0% YoY). Sales on the other hand came in at Rs 20 bn (up 0.6% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (1QFY21); Net Profit Up 48.6% (Quarterly Result Update)

Jul 31, 2020 | Updated on Jul 31, 2020

For the quarter ended June 2020, TORRENT PHARMA has posted a net profit of Rs 3 bn (up 48.6% YoY). Sales on the other hand came in at Rs 21 bn (up 1.7% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (3QFY20); Net Profit Up 2.0% (Quarterly Result Update)

Jan 28, 2020 | Updated on Jan 28, 2020

For the quarter ended December 2019, TORRENT PHARMA has posted a net profit of Rs 3 bn (up 2.0% YoY). Sales on the other hand came in at Rs 20 bn (down 4.1% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

BIOCON Announces Quarterly Results (3QFY20); Net Profit Up 1.2% (Quarterly Result Update)

Jan 24, 2020 | Updated on Jan 24, 2020

For the quarter ended December 2019, BIOCON has posted a net profit of Rs 2 bn (up 1.2% YoY). Sales on the other hand came in at Rs 17 bn (up 13.5% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

More Views on News

Most Popular

'Essential' Smallcap Stock Recommendations(Profit Hunter)

Jan 8, 2021

The smallcap rally has enough steam left in it. If you haven't joined yet, it is still not too late.

Is Nifty Forming a Top(Fast Profits Daily)

Jan 8, 2021

The charts are telling the bulls to be cautious.

Why Gold Hit Lower Circuit(Fast Profits Daily)

Jan 11, 2021

Were you shocked that bullion prices hit lower circuits on Friday on the MCX? Find out why it happened...

A Rare Chance to Invest in Potential Multibaggers in 2021(Profit Hunter)

Jan 11, 2021

Our ace stock picker is ready to capitalise on a big growth opportunity.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

BIOCON SHARE PRICE


Jan 21, 2021 10:40 AM

TRACK BIOCON

COMPARE BIOCON WITH

MARKET STATS